Evidence map›Paper›PMID 37226642›Full record

ArticleJournal of cellular and molecular medicine2023

KRAS

Chang Cai, Shuo Yao, Yanmei Zou, Hui Lu, Xiuqiong Chen, Yali Wang, Kun Zheng, Feng Zhu, Yihua Wang, Hua Xiong and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. KRASJournal of cellular and molecular medicine · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Chang CaiDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Shuo YaoDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yanmei ZouDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hui LuWuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xiuqiong ChenDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yali WangDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Kun ZhengDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Feng ZhuCancer Research Institute, The Affiliated Hospital of Guilin Medical University, Guilin, China.
Yihua WangBiological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK.
Hua XiongDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.ORCID 0000-0002-0087-9452
Junfei ZhuDepartment of Respiratory Medicine, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.
Tongji Hospital · CNGuilin Medical University · CNNIHR Southampton Biomedical Research Centre · GBTaizhou Central Hospital · CNUniversity Hospital Southampton NHS Foundation Trust · GBWenzhou Medical University · CNWuhan Children's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

KRAS mutation is the most frequent type of genetic mutation in non-small cell lung cancer (NSCLC), especially in lung adenocarcinoma. However, KRAS mutation can affect many biological processes and the mechanisms underlying KRAS mutation-mediate carcinogenesis in NSCLC have not been fully understood. In this research, we found that KRAS

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsCarcinogenesisExtracellular Signal-Regulated MAP KinasesHumansKiller Cells, Lymphokine-ActivatedMitogen-Activated Protein Kinase KinasesMutationProto-Oncogene Proteins p21(ras)QuinolonesThiophenesExtracellular Signal-Regulated MAP KinasesKRAS protein, humanMitogen-Activated Protein Kinase KinasesOTS514PDZ-binding kinaseProto-Oncogene Proteins p21(ras)QuinolonesThiophenesKRAS G12CNSCLCproliferationTOPK

Identifiers

PMID37226642
PMCPMC10273069
OpenAlexW4378172239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.